Go Pro

Nutex Health Inc. (NASDAQ:NUTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Nutex Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Nutex Health has a “Moderate Buy” consensus rating from five brokerages, with three buy ratings and two holds. The average 12-month price target is $268.33, including Lake Street Capital’s raised $310 target and B. Riley’s $290 target.
  • Institutional investors increased their involvement during the second quarter, including new positions from Empowered Funds, United Capital Financial Advisors, Corient Private Wealth and Bank of America. Institutions collectively own 5.32% of the company.
  • Nutex Health reported quarterly EPS of $9.38, beating the $4.95 consensus estimate, while revenue of $210.75 million fell slightly short of expectations. Shares opened at $190.62, near their 52-week high of $204.00.
  • Five stocks to consider instead of Nutex Health.

Shares of Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $268.3333.

Several equities analysts recently issued reports on NUTX shares. Weiss Ratings upgraded Nutex Health from a "hold (c)" rating to a "hold (c+)" rating in a research note on Tuesday, July 28th. Zacks Research upgraded Nutex Health to a "hold" rating in a research note on Monday, June 29th. Lake Street Capital reiterated a "buy" rating and issued a $310.00 price objective (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. Wall Street Zen downgraded shares of Nutex Health from a "strong-buy" rating to a "buy" rating in a research note on Monday, July 20th. Finally, B. Riley Financial assumed coverage on Nutex Health in a research note on Friday, June 26th. They issued a "buy" rating and a $290.00 target price on the stock.

View Our Latest Stock Analysis on NUTX

Institutional Investors Weigh In On Nutex Health

Institutional investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Nutex Health by 81.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 4,399 shares of the company's stock worth $752,000 after buying an additional 1,980 shares in the last quarter. Empowered Funds LLC bought a new stake in Nutex Health during the second quarter worth about $7,720,000. United Capital Financial Advisors LLC acquired a new position in Nutex Health during the second quarter valued at approximately $722,000. Corient Private Wealth LP bought a new position in Nutex Health in the second quarter valued at approximately $1,142,000. Finally, Bank of America Corp DE acquired a new position in shares of Nutex Health during the 2nd quarter worth approximately $1,752,000. Institutional investors own 5.32% of the company's stock.

Nutex Health Price Performance

NASDAQ NUTX opened at $190.62 on Thursday. Nutex Health has a 1 year low of $77.21 and a 1 year high of $204.00. The business's fifty day moving average is $165.64 and its two-hundred day moving average is $130.79. The stock has a market capitalization of $1.31 billion, a P/E ratio of 7.48 and a beta of 0.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.96 and a current ratio of 5.00.

Nutex Health (NASDAQ:NUTX - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $9.38 EPS for the quarter, topping the consensus estimate of $4.95 by $4.43. The business had revenue of $210.75 million during the quarter, compared to analysts' expectations of $215.03 million. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%. On average, research analysts forecast that Nutex Health will post 30.11 earnings per share for the current fiscal year.

About Nutex Health

(Get Free Report)

Nutex Health, Inc NASDAQ: NUTX is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.

Read More

Analyst Recommendations for Nutex Health (NASDAQ:NUTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Nutex Health Right Now?

Before you consider Nutex Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.

While Nutex Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines